Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

7.920 +0.260 (+3.39%)
Streaming Delayed Price Updated: 1:19 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Reports 88 Percent Q2 Loss Drop ↗
Via The Motley Fool
News headline image
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy ↗
Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application. 
Via Stocktwits
News headline image
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? ↗
Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results. 
Via Benzinga
News headline image
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish ↗
The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024. 
Via Stocktwits
News headline image
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Upcoming Investor Conferences
From Candel Therapeutics
Via GlobeNewswire
News headline image
Top movers in Wednesday's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients ↗
Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile. 
Via Benzinga
News headline image
Candel Therapeutics Shares Are Down Today: What's Going On? ↗
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409. 
Via Benzinga
News headline image
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism ↗
The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.